- ►nih.gov GD Barish, VA Narkar, RM Evans - Journal of Clinical Investigation, 2006 - Am Soc Clin Investig Obesity is a growing threat to global health by virtue of its association with
insulin resistance, glucose intolerance, hypertension, and dyslipidemia,
collectively known as the metabolic syndrome or syndrome X. The nuclear ... Cited by 240 - Related articles - BL Direct - All 7 versions
- ►nih.gov VA Narkar, M Downes, RT Yu, E Embler, YX … - Cell, 2008 - Elsevier The benefits of endurance exercise on general health make it desirable to
identify orally active agents that would mimic or potentiate the effects of
exercise to treat metabolic diseases. Although certain natural compounds, ... Cited by 75 - Related articles - All 12 versions
- ►ahajournals.org DL Sprecher, C Massien, G Pearce, AN Billin, … - Arteriosclerosis, Thrombosis, and Vascular Biology, 2007 - Am Heart Assoc From the Department of Discovery Medicine (DLS, CM, GP, TGJ), Cardiovascular and
Urogenital Center of Excellence in Drug Discovery, GlaxoSmithKline, King of
Prussia, Pa; the Department of High-throughput Biology (ANB), ... Cited by 71 - Related articles - All 6 versions
- ►nih.gov KA Burns, JP Vanden Heuvel - BBA-Molecular and Cell Biology of Lipids, 2007 - Elsevier Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear
receptor superfamily of transcription factors that respond to specific ligands
by altering gene expression in a cell-, developmental- and sex-specific ... Cited by 60 - Related articles - All 5 versions
T Fritz, DK Krämer, HKR Karlsson, D Galuska, … - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 41 - Related articles - BL Direct - All 4 versions
KL Kirk - Journal of Fluorine Chemistry, 2006 - Elsevier Advances in the development of newly developed fluorinated drugs, approved or in
clinical trials, as organized by biological targets/disease states, are
reviewed. In a few cases, compounds in early stages of development will be ... Cited by 41 - Related articles - All 4 versions
HE Hollingshead, RL Killins, MG Borland, EE … - Carcinogenesis, 2007 - Oxford Univ Press Page 1. 1 Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands
do not potentiate growth of human cancer cell lines ... Cited by 34 - Related articles - All 3 versions
S Takahashi, T Tanaka, T Kodama, J Sakai - Pharmacological research, 2006 - Elsevier The development of new treatments for metabolic syndrome is urgent project for
decreasing the prevalence of coronary heart disease and diabetes mellitus in the
advanced countries. Peroxisome proliferator-activated receptor (PPAR)α and ... Cited by 34 - Related articles - All 5 versions
- ►diabetesjournals.org M Vänttinen, P Nuutila, T Kuulasmaa, J … - Diabetes, 2005 - Am Diabetes Assoc The peroxisome proliferator–activated receptors (PPARs) belong to a
superfamily of nuclear receptors. It includes PPAR-δ, a key regulator of fatty
acid oxidation and energy uncoupling, universally expressed in different ... Cited by 34 - Related articles - BL Direct - All 4 versions
- ►jbc.org DK Kramer, L Al-Khalili, B Guigas, Y Leng, … - Journal of Biological Chemistry, 2007 - ASBMB The peroxisome proliferator-activated receptor (PPAR) has been implicated in the
regulation of lipid metabolism in skeletal muscle. Furthermore, activation of
PPAR has been proposed to improve insulin sensitivity and reduce glucose ... Cited by 29 - Related articles - All 8 versions
